The Spring issue of Cardiology magazine highlights the latest developments in peripheral vascular disease (PVD) treatment and management. “In 2015, three major pivotal trials confirmed the safety and efficacy of paclitaxel-coated balloons in the endovascular treatment of femoropopliteal artery disease: the IN.PACT SFA trial, the LEVANT 2 trial, and the five-year follow-up of the THUNDER trial.” Thosaphol Limpijankit, MD, FACC, explains that “these trials demonstrated that while drug-coated balloons are generally safe and superior to standard balloon angioplasty, there are many unanswered questions. Future studies need to look at longer lesions, densely calcified lesions, or in-stent restenosis, and consider comparison with bare metal stents and drug-eluting stents.” Read more on ACC.org. Get the full issue at ACC.org/Cardiology.